entertainment -WSS

entertainment

author：fashion 2025-09-30 21:27:13 - browse：84619

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Sanofi seeks simpler, safer CRISPR sickle cell cure

WSS

How Medicaid coverage policies for immigrants impact new moms

Biden tests positive for Covid

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Eli Lilly reports tirzepatide MASH success during Q4 earnings

How Medicaid coverage policies for immigrants impact new moms

Listen: Wegovy in the brain & pivotal Alzheimer's data

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

hotspot

At least 13 dead in Texas as scorching temps continue

Juul documents reveal insider tactics on political lobbying

Malaria cases in Florida and Texas: Here’s what you need to know

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

23andMe had bad news about my health. I wish a person had delivered it

Congress might make insulin pumps more accessible to the blind

Medicare details structure of new drug price negotiation program

Why don't Americans have at

Medicare details structure of new drug price negotiation program

Custom gene therapy hints at new path for rare disease treatments

hotspot

Medicare has a new plan to address drug shortages

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

A public scorecard can help hold safety

Ebola vaccine can save some who are already sick, per new study

Wikipedia

entertainment

explore

focus